Roche Reports 17% Jump in Net Income for First Half of 2025

Swiss pharmaceutical giant Roche reported a 17% increase in net income to 7.8 billion Swiss francs ($9.85 billion) in the first half of 2025, driven by strong sales of asthma and breast cancer treatments. Sales exceeded forecasts, rising 4% to 30.9 billion Swiss francs. The company confirmed its full-year outlook and advanced four potentially "practice-changing" drugs into the final stage of clinical development.

Swiss pharmaceutical giant Roche reported a 17% increase in net income to 7.8 billion Swiss francs ($9.85 billion) in the first half of 2025, driven by strong sales of asthma and breast cancer treatments. Sales exceeded forecasts, rising 4% to 30.9 billion Swiss francs. The company confirmed its full-year outlook and advanced four potentially "practice-changing" drugs into the final stage of clinical development.

Roche's Pharmaceuticals Division sales rose by 10% (6% in CHF), with key drivers including Phesgo (breast cancer), Xolair (food allergies), Hemlibra (haemophilia A), Vabysmo (severe eye diseases), and Ocrevus (multiple sclerosis) [1]. The Diagnostics Division sales were stable (-3% in CHF), as demand for pathology solutions and blood screening tests offset healthcare pricing reforms in China [1].

Core operating profit increased by 11% (6% in CHF) to 12.0 billion Swiss francs, driven by higher sales and effective cost management. Core earnings per share showed significant growth of 12% (8% in CHF) [1].

The company also announced several key approvals and positive data for various therapies, including Itovebi for advanced breast cancer, Evrysdi tablet for spinal muscular atrophy, and Susvimo for diabetic retinopathy [1]. Roche's CEO, Thomas Schinecker, noted the company's strong growth momentum and resilience, driven by its innovative on-market portfolio and pipeline.

The appreciation of the Swiss franc against most currencies had an adverse impact on results when reported in Swiss francs compared to constant exchange rates. However, the company expects an increase in Group sales in the mid single-digit range (CER) for 2025, with core earnings per share targeted to develop in the high single-digit range (CER). Roche also expects to further increase its dividend in Swiss francs [1].

References:
[1] https://www.roche.com/media/releases/med-cor-2025-07-24